John Overdeck’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.95M | Buy |
+18,825
| New | +$4.44M | ﹤0.01% | 1974 |
|
|
2025
Q2 | – | Sell |
-2,800
| Closed | -$294K | – | 3376 |
|
|
2025
Q1 | $294K | Sell |
2,800
-207
| -7% | -$23.4K | ﹤0.01% | 2724 |
|
|
2024
Q4 | $322K | Buy |
3,007
+7
| +0.2% | +$791 | ﹤0.01% | 2713 |
|
|
2024
Q3 | $300K | Hold |
3,000
| – | – | ﹤0.01% | 2669 |
|
|
2024
Q2 | $253K | Buy |
+3,000
| New | +$239K | ﹤0.01% | 2657 |
|
|
2024
Q1 | – | Sell |
-3,000
| Closed | -$214K | – | 3222 |
|
|
2023
Q4 | $214K | Sell |
3,000
-3,300
| -52% | -$195K | ﹤0.01% | 2813 |
|
|
2023
Q3 | $377K | Sell |
6,300
-1,000
| -14% | -$65.8K | ﹤0.01% | 2399 |
|
|
2023
Q2 | $526K | Hold |
7,300
| – | – | ﹤0.01% | 2306 |
|
|
2023
Q1 | $537K | Sell |
7,300
-33,465
| -82% | -$2.38M | ﹤0.01% | 2174 |
|
|
2022
Q4 | $2.72M | Buy |
40,765
+34,552
| +556% | +$2.25M | 0.01% | 1148 |
|
|
2022
Q3 | $334K | Sell |
6,213
-25,813
| -81% | -$1.52M | ﹤0.01% | 1927 |
|
|
2022
Q2 | $1.78M | Buy |
+32,026
| New | +$1.82M | 0.01% | 1261 |
|
|
2022
Q1 | – | Sell |
-8,656
| Closed | -$834K | – | 3569 |
|
|
2021
Q4 | $834K | Hold |
8,656
| – | – | ﹤0.01% | 2726 |
|
|
2021
Q3 | $752K | Hold |
8,656
| – | – | ﹤0.01% | 2888 |
|
|
2021
Q2 | $708K | Sell |
8,656
-1,404
| -14% | -$117K | ﹤0.01% | 2793 |
|
|
2021
Q1 | $957K | Sell |
10,060
-44,944
| -82% | -$4.25M | ﹤0.01% | 2369 |
|
|
2020
Q4 | $3.41M | Sell |
55,004
-8,617
| -14% | -$491K | 0.01% | 1152 |
|
|
2020
Q3 | $3.78M | Sell |
63,621
-65,677
| -51% | -$4.48M | 0.01% | 935 |
|
|
2020
Q2 | $9.02M | Sell |
129,298
-32,490
| -20% | -$2.06M | 0.04% | 424 |
|
|
2020
Q1 | $7.34M | Sell |
161,788
-114,417
| -41% | -$6.49M | 0.06% | 355 |
|
|
2019
Q4 | $18M | Buy |
276,205
+113,856
| +70% | +$7.61M | 0.05% | 401 |
|
|
2019
Q3 | $10.1M | Sell |
162,349
-177,267
| -52% | -$11.1M | 0.03% | 541 |
|
|
2019
Q2 | $24.2M | Sell |
339,616
-91,118
| -21% | -$6.71M | 0.08% | 318 |
|
|
2019
Q1 | $33.8M | Sell |
430,734
-15,273
| -3% | -$1.16M | 0.11% | 236 |
|
|
2018
Q4 | $37.8M | Buy |
446,007
+304,619
| +215% | +$32.5M | 0.15% | 175 |
|
|
2018
Q3 | $24.2M | Sell |
141,388
-49,156
| -26% | -$7.41M | 0.07% | 373 |
|
|
2018
Q2 | $24.6M | Sell |
190,544
-48,981
| -20% | -$5.47M | 0.07% | 347 |
|
|
2018
Q1 | $24.7M | Buy |
+239,525
| New | +$23.7M | 0.08% | 293 |
|
|
2017
Q4 | – | Sell |
-94,415
| Closed | -$8.02M | – | 3291 |
|
|
2017
Q3 | $8.02M | Buy |
94,415
+56,357
| +148% | +$4.46M | 0.03% | 603 |
|
|
2017
Q2 | $2.88M | Buy |
+38,058
| New | +$2.66M | 0.01% | 1182 |
|
|
2016
Q3 | – | Sell |
-174,934
| Closed | -$13M | – | 3253 |
|
|
2016
Q2 | $13M | Buy |
174,934
+126,083
| +258% | +$9.36M | 0.06% | 400 |
|
|
2016
Q1 | $3.26M | Buy |
48,851
+16,849
| +53% | +$1.02M | 0.02% | 902 |
|
|
2015
Q4 | $2.16M | Buy |
+32,002
| New | +$1.98M | 0.01% | 1051 |
|
|
2015
Q3 | – | Sell |
-70,732
| Closed | -$4.45M | – | 2484 |
|
|
2015
Q2 | $4.45M | Sell |
70,732
-66,794
| -49% | -$3.64M | 0.02% | 772 |
|
|
2015
Q1 | $6.62M | Buy |
137,526
+60,672
| +79% | +$2.32M | 0.03% | 608 |
|
|
2014
Q4 | $2.55M | Sell |
76,854
-36,640
| -32% | -$1.19M | 0.01% | 921 |
|
|
2014
Q3 | $3.33M | Buy |
113,494
+64,660
| +132% | +$2.15M | 0.01% | 729 |
|
|
2014
Q2 | $1.9M | Buy |
48,834
+11,107
| +29% | +$451K | 0.01% | 1043 |
|
|
2014
Q1 | $1.58M | Buy |
+37,727
| New | +$1.57M | 0.01% | 1035 |
|
|
2013
Q4 | – | Sell |
-71,026
| Closed | -$1.92M | – | 2282 |
|
|
2013
Q3 | $1.92M | Buy |
+71,026
| New | +$2M | 0.01% | 794 |
|
Other funds holding LGND
JT
CAM
John Overdeck's LGND Position: Q2 2026 in Review
John Overdeck opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 18,825 shares worth $5.95M. The stake represents ﹤0.01% of the portfolio and ranks #1974 among its holdings. This is a return to the name: John Overdeck previously reported a position in LGND as recently as Q1 2025.
John Overdeck first reported a position in LGND in Q3 2013 and has held it in 40 quarters since. The position peaked at $37.8M in Q4 2018. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- John Overdeck held 18,825 shares of Ligand Pharmaceuticals worth $5.95M as of Q2 2026.
- Ligand Pharmaceuticals was a new John Overdeck position in Q2 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #1974 holding.
- John Overdeck first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
- John Overdeck's Ligand Pharmaceuticals position peaked at $37.8M in Q4 2018.
- 413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.